


## INTRODUCTION

- The HIV Prevention Trials Network (HPTN) 065 (TLC-Plus) study sought to evaluate the feasibility of an enhanced community-level test, link to care, plus treat strategy in the U.S., and efficacy of financial incentives for improving linkage to care and viral suppression.<sup>1</sup>
- We conducted baseline (2010-11) and follow-up (2013) surveys among ART-prescribing clinicians at sites participating in the HPTN 065 (TLC-Plus) study in the Bronx, NY and Washington, DC to assess:
- » practices for recommending ART to their HIV-infected patients
- » attitudes concerning early ART initiation to prevent HIV transmission
- During the 4-year period (2010-2013) between the two surveys, new scientific findings were published and recommendations for ART initiation were updated:
- » HPTN 052 demonstrated dramatic reduction in sexual HIV transmission with ART use<sup>2</sup>
- » The Department of Health and Human Services (DHHS) recommended universal ART for all HIVinfected persons in the U.S.<sup>3</sup>

### **METHODS**

- ART-prescribing clinicians at 39 HIV care sites in the Bronx, NY and Washington, DC participating in the HPTN 065 (TLC-Plus) study completed a brief anonymous 29-item internet survey.<sup>4</sup>
- Baseline and follow-up survey data were not linked by respondent.
- We used t-tests and Kruskal-Wallis tests to assess for statistical differences in distribution of responses across the two surveys.

Figure 1: Study Flow of HIV Clinician Recruitment and Follow-up in 2 US Cities



<sup>2</sup> FHI 360. Durham. NC

### Table 1: Demographic Characteristics of Respondents Baseline Follow-up (n=165) Variable (n=141) P-value 56.7 59.4 0.51 Female (%) Median age (years) 0.73 47 47 66.1 White race/ethnicity (%) 61.7 0.28 Specialty physician (%) 33.3 0.51 41.8 25.5 32.1 0.51 Primary care physician (%) Practicing in public clinic (%) 44.8 50.4 0.51 Median duration caring for 13.3 15.0 0.11 HIV-infected patients (years) ART training in past 3 53.9 58.2 0.58 months (%)

### Table 2: Number of Patients Initiated on ART in Past 12 Months

**Estimated** past year

Median [IQR] (no. of respon

Estimated number of patients initiated on ART with the main goal of making it less likely that they would pass on HIV to their partners

Median [IQR] (no. of respon

### Table 3: Factors Influencing ART Initiation

### Would you g **HIV-infected**

With CD4 cou

Irrespective of

Which factor would otherw

Patient having with partner(s status

Patient in an sexual partner



# Providers' Attitudes and Practices Related to ART Use for HIV Care and Prevention

Kate Buchacz<sup>1</sup>, Jennifer Farrior<sup>2</sup>, Geetha Beauchamp<sup>3</sup>, Laura McKinstry<sup>3</sup>, Ann E Kurth<sup>4</sup>, Barry S Zingman<sup>5</sup>, Fred Gordin<sup>6</sup>, Deborah Donnell<sup>3</sup>, Wafaa El-Sadr<sup>7</sup>, Bernard Branson<sup>1</sup> for the HPTN 065 (TLC-Plus) Study Team

<sup>1</sup>US Centers for Disease Control and Prevention, Atlanta, GA

<sup>3</sup> Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA

<sup>4</sup> New York University College of Nursing, New York, NY <sup>5</sup> Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY

	Baseline	Follow-up	P-value
umber of patien	ts provider in	itiated on Al	RT in the
] nses)	10 [5 - 30] (n=160)	20 [8 - 36] (n=138)	0.04

] nses)	0 [0 - 3] (n=147)	3 [0 - 8] (n=131)	<0.01
•	· · · · · ·	. ,	

	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value	
generally recommend ART be initiated for a typical patient?				
unt ≤ 500 cells/mm <sup>3</sup>	55.8	68.1	0.04	
of CD4 cell count	14.5	68.1	<0.01	
r would lead you to initiate ART earlier than you wise?				
g unprotected sex s) of unknown HIV	63.6	81.6	<0.01	
HIV discordant ership	75.2	87.2	0.01	

	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value
If a patient tells me that he or she is engaging in high risk behaviors, I am more likely to recommend initiating ART, irrespective of their CD4+ count.			
Strongly agree	23.0	41.1	
Agree	47.9	44.0	
Disagree	24.8	9.9	<0.01
Strongly disagree	1.2	2.1	
Did not answer	3.0	2.8	

### Table 5: ART for Community Benefit

	Baseline (n=165) (%)	Follow-up (n=141) (%)	P-value
Early initiation of ART can slow community by making patients			rs
Strongly agree	64.8	87.9	
Agree	29.7	9.2	
Disagree	2.4	0.0	<0.01
Strongly disagree	0.0	0.0	
Did not answer	3.0	2.8	

### **KEY RESULTS**

- The percentage of providers who reported recommending ART initiation irrespective of CD4 cell count increased from baseline to follow-up who would initiate ART earlier for patients having unprotected sex with partners of unknown HIV status (63.6% vs. 81.6%, p<0.01) and for those in HIV-discordant sexual partnerships (75.2% vs. 87.2%, p<0.01).
- The percentage of providers who strongly agreed with the statement "Early initiation of ART can to 87.9%, p<0.01).
- Providers reported initiating more patients on ART in the past year with the main goal of making it p<0.01).

<sup>6</sup> Veterans Affairs Medical Center and George Washington University, Washington, DC <sup>7</sup> ICAP at Columbia University, New York, NY

## RESULTS


### Table 4: ART for High Risk Behaviors

(14.5% vs. 68.1%, p<0.01) as did the percentage

slow the spread of HIV in a community by making patients less infectious to others" also rose (64.8%

less likely that patients would transmit HIV to their sexual partners (median of zero vs. three patients, Figure 2: ART for Reducing HIV Transmission (follow-up results, n = 141)

> "Because ART reduces the risk of transmission, I routinely recommend my HIV-infected patients"



### LIMITATIONS

- Could not link individual baseline and follow responses due to anonymous nature of the estimated 38% of clinicians were surveyed determined by question "did you take this survey once before in 2010"?)
- Statistical comparisons assumed independent cross sectional surveys: we could not adjust for repeated observations since survey was anonymous
- Could not stratify changes in outcomes by jurisdiction

The HIV Prevention Trials Network is sponsored by the U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health and the U.S. National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.





	SUMMARY and CONCLUSION
HIV ART to	<ul> <li>In the follow-up survey, respondents were significantly more likely to prescribe ART:</li> <li>» irrespective of CD4 status</li> <li>» when patients reported unprotected sex</li> <li>» for patients in HIV discordant relationships</li> </ul>
	<ul> <li>Almost 90% of respondents "strongly agreed" that ART can reduce transmission within a community (versus 65% at baseline)</li> </ul>
	<ul> <li>From 2011 to 2013, a greater percentage of ART-prescribing providers in the two jurisdictions supported initiating ART for all HIV-infected patients and using ART to prevent transmission, consistent with new scientific evidence and changes in HIV treatment recommendations during the conduct of HPTN 065.<sup>2,3</sup></li> </ul>
	REFERENCES
	<sup>1</sup> Donnell et al. Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. Open AIDS J. 2012;6:122-30.
	<sup>2</sup> Cohen et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEJM 2011; 365(6):493-505
	<sup>3</sup> Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents <u>http://aidsinfo.nih.gov/contentfiles/Ivguidelines/</u>
Disagree	adultandadolescentgl.pdf
r	<sup>4</sup> Kurth et al. Clinician Practices and Attitudes regarding Early Antiretroviral Therapy in the US. JAIDS 2012;61:e65-e69.
	ACKNOWLEDGMENTS
v-up survey (an	We sincerely thank the clinicians who participated in this survey.
twice as	LIDTNI OGE (TLC Dlug) Study is supported by NUAID NUDA

HPIN 065 (ILC-Plus) Study is supported by NIAID, NIDA, and NIMH (Cooperative Agreement #UM1 AI068619; #UM1 AI068617) and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases, the National Institutes of Health. or the Centers for Disease Control and Prevention.